Multiple agent diabetes therapy

• US 20060074013A1
• Filed: 06/24/2005
• Published: 04/06/2006
• Est. Priority Date: 06/25/1999
• Status: Active Grant

• Current Assignee: Andreas H.R. Pfuetzner, William P Van Antwerp
• Original Assignee: Andreas H.R. Pfuetzner, William P Van Antwerp
• Inventors: Van Antwerp, William P., Pfuetzner, Andreas H.R.
• Granted Patent: US 7,323,543 B2
• Time in Patent Office: Days
• US Class Current: 514/5.900
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

Claims

1. A method of treating diabetes comprising the step of administering to a patient in need of such treatment a pharmaceutical composition comprising:

agent (i) selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,

agent (ii) selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

agent (iii) an insulin sensitizer.

2. The method of claim 1 wherein said composition is administered to said patient by a medication infusion pump.

3. The method of claim 2 wherein said medication infusion pump is reusable.

4. The method of claim 2 wherein said medication infusion pump is non-reusable.

5. The method of claim 2 wherein said medication infusion pump is implantable.

6. The method of claim 2 wherein said medication infusion pump is externally mountable.

7. The method of claim 1 wherein said composition is administered continually.

8. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1 and a non-ionic surfactant.

9. The method of claim 1 wherein said diabetes is type 2 diabetes.

10. A method of treating diabetes comprising the step of administering to a patient in need of such treatment at least two pharmaceutical compositions (a)-(c), wherein:

composition (a) comprises;

(i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and

(ii) a pharmaceutically acceptable carrier,

composition (b) comprises;

(i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

(ii) a pharmaceutically acceptable carrier, and

composition (c) comprises;

(i) an insulin sensitizer, and

(ii) a pharmaceutically acceptable carrier.

11. The method of claim 10 wherein each of said compositions is administered to said patient using a separate delivery device.

12. The method of claim 11 wherein each said delivery device is a medication infusion pump.

13. The method of claim 10 wherein each of said compositions is administered at a different rate.

14. The method of claim 10 wherein each of said compositions is administered continually.

15. The method of claim 10 wherein compositions (a) and (1) are administered to said patient.

16. The method of claim 15 wherein said composition (b) further comprises at least one pharmaceutically acceptable non-ionic surfactant.

17. The method of claim 10 wherein compositions (a) and (c) are administered to said patient.

18. The method of claim 10 wherein compositions (b) and (c) are administered to said patient.

19. The method of claim 10 wherein compositions (a), (b) and (c) are administered to said patient.

20. A method of making a pharmaceutical composition useful in treating diabetes, said method comprising the step of combining at least two of agents (i)-(iii), wherein:

agent (i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,

agent (ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

agent (iii) is an insulin sensitizer.

21. The method of claim 20 wherein said agents are combined with a pharmaceutically acceptable carrier.

22. The method of claim 20 wherein agents (i) and (ii) are combined.

23. The method of claim 21 wherein agents (i) and (ii) are combined with a pharmaceutically acceptable non-ionic surfactant.

24. The method of claim 21 wherein agents (i) and (iii) are combined.

25. The method of claim 21 wherein agents (ii) and (iii) are combined.

26. The method of claim 21 wherein agents (i), (ii) and (iii) are combined.

27. A method of treating diabetes and at least one side effect thereof which comprises the step of administering to a patient in need of such treatment a pharmaceutical composition comprising

(a) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment,

(b) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, wherein said agent is effective in treating said side effect, and

(c) a pharmaceutically acceptable non-ionic surfactant.